Mast Global Battery Recycling & Production ETF EV
Set alert
21.85 USD +0.06 +0.28%
As of Jun 11, 9:55 AM ET
21.85 Day range 21.85
21.43 52-week range 28.62
- YTD
- -8.64%
- 1 year
- -7.28%
- Open
- 22.02
- Prev close
- 21.78
- Mkt cap
- 6.87M
- Vol
- 76
- Avg vol
- 1.53K
- EPS
- 0.00
- P/E
- 12.91
- Div yield
- 0.00%
More statistics
- Low
- 21.85
- High
- 21.85
- Forward P/E
- 0.00
- Beta
- 0.00
- Short ratio
- 0.00
- Dividend
- 0.00
- Ex-div date
- Earnings
- Feb 24, 2021
- 50-d avg
- 25.37
- 200-d avg
- 24.26
Key statistics
- Market cap
- 0
- Enterprise value
- 0
- Trailing P/E
- 12.91
- Forward P/E
- 0.00
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- EPS (TTM)
- 0.00
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Shares outstanding
- 0
- Short % of float
- 0.00%
- 50-day average
- 25.37
- 200-day average
- 24.26
Next earnings
Feb 24, 2021
Expected Feb 24, 2021. Consensus EPS estimate 0.84.
Financials — quick view
EV Revenue — quarterly 451.08M
EV Net income — quarterly -35.93M
EV EPS — quarterly -0.34
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 24, 2021 | Jan 1, 2021 | 0.84 | — | — | — |
| Nov 24, 2020 | Oct 1, 2020 | 0.86 | — | — | — |
| Aug 26, 2020 | Jul 1, 2020 | 0.77 | — | — | — |
| May 20, 2020 | Apr 1, 2020 | 0.71 | — | — | — |
| Feb 26, 2020 | Jan 1, 2020 | 0.86 | — | — | — |
| Nov 26, 2019 | Oct 1, 2019 | 0.89 | — | — | — |
About Mast Global Battery Recycling & Production ETF
The fund will invest at least 80% of its assets in companies that derive at least 50% of its revenue from the battery recycling and production business and/or devotes at least 50% of its assets to the battery recycling and production business. The fund is non-diversified.
News
- Tesla Tailwinds Could Propel This New ETF
- IMFINZI® (durvalumab) plus tarlatamab-dlle reduced the risk of death by 58% in 1st-line extensive-stage small cell lung cancer in the DeLLphi-305 Phase III trial
- Perioperative IMFINZI® (durvalumab) plus neoadjuvant enfortumab vedotin reduced risk of recurrence by 49% and risk of death by 42% in muscle-invasive bladder cancer
- Plug in, get paid: Duke Energy Florida program offers bill credits for customers charging EVs at certain times
- AHF Debuts ‘Wellness on Wheels' - New EV Mobile Clinic During ‘Pride on Paradise'
- PCB Technologies to Acquire Silicon Valley's Gorilla Circuits for an Enterprise Value of USD 120 million, Establishing US Manufacturing Footprint
- AstraZeneca Completes $2 Billion Equity Investment in Summit Therapeutics
- Summit Therapeutics Announces Clinical Trial Collaboration with AstraZeneca and Daiichi Sankyo to Evaluate Ivonescimab in Combination with TROP2-Directed ADC Datroway
- Service developed to support decision-making for corporate EV fleet adoption
- Ivonescimab Monotherapy Demonstrates a Statistically Significant & Clinically Meaningful Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in Akeso's HARMONi-2 Study Condu
Your note
Sign in to keep a note on EV — it syncs with the Stock Master app.